

OPG Human

Osteoprotegerin Human Recombinant
GRF0288

Product Overview

Name OPG Human

Description

Osteoprotegerin Human Recombinant

Accession (Primary) [O00300](#)

Synonyms

TNFRSF11B, OPG, OCIF, Osteoclastogenesis inhibitory factor, Osteoprotegerin, TR1, MGC29565.

Introduction

Osteoprotegerin acts as decoy receptor for rankl and thereby neutralizes its function in osteoclastogenesis. OPG inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local rankl/opg ratio. Osteoprotegerin may also play a role in preventing arterial calcification. May act as decoy receptor for trail and protect against apoptosis. Trail binding blocks the inhibition of osteoclastogenesis.

Source

HEK293 Cells.

Physical Appearance

Sterile Filtered White lyophilized (freeze-dried) powder.

Formulation

OPG filtered (0.4 µm) and lyophilized from 0.5mg/ml solution in PBS, pH7.5 and 5% (w/v) Trehalose.

Stability

Store lyophilized protein at -20°C. Aliquot the product after reconstitution to avoid repeated freezing/thawing cycles . Reconstituted protein can be stored at 4°C for a limited period of time; it does not show any change after two weeks at 4°C.

Purity

Greater than 90.0% as determined by SDS-PAGE.

Amino acid sequence

PGDYKDDDDKPAGETFPKYLHYDEETSHQLLCDKCPPGTYLKQHCTAKWKTVCAPCPDHYTDSWHTSDECLYC
SPVCKELQYVKQECNRTHNRVCECKEGRYLEIEFCLKHRSCPPGFGVVQAGTPERNVCKRCPDGGFFSNETSSKAP
CRKHTNCSVFGLLLTQKGNATHDNICSGNSESTQKCGIDVTLCEEAFRFAVPTKFTPNWLSVLVDNLPGTKVNAESV
ERIKRQHSSQEQTFFQLLKLWKHQNKDQDIVKKIIQDIDLCENSVQRHIGHANLTFEQLRSLMESLPGKKVGAEDIEK

TIKACKPSDQILKLLSLWRIKNGDQDTLKGLMHALKHSKTYHFPKTVTQSLKKTIRFLHSFTMYKLYQKLFLEMIGNQ

Solubility

It is recommended to add deionized water to prepare a working stock solution of approximately 0.5mg/ml and let the lyophilized pellet dissolve completely.

Precautions

OPG Human is for research use only and not for use in diagnostic or therapeutic procedures.

Target Information: ([O00300](#))